Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00171795 | Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment | PHASE3 | COMPLETED | 67 | — | — | Nov 1, 2002 | May 1, 2005 | Nov 23, 2011 | - | — |
| Name | Type | Description |
|---|---|---|
| Rivastigmine | DRUG | - |
Inclusion Criteria: * Traumatic brain injury confirmed by available brain imaging (CT or MRI) and be at least 52 weeks post injury * Neuropsychologic disturbances indicated by: impaired memory (reduction of below 1 standard deviation (SD) of the mean on the California Verbal Learning Test (CVLT) an...